Evaluation of the COVIDSeq Test in Saliva Specimens From COVID-19 Asymptomatic Illumina Personnel

Completed

• Conditions: SARS-CoV-2
• Interventions: Diagnostic Test: COVIDSeq Test

• Registration Number: NCT04561089
• Lead Sponsor: Illumina, Inc.

Brief Summary

"This is a prospective, multi-center specimen collection study. Subjects 18 years of age or older who do not have symptoms of COVID-19 will be enrolled. Two nasal swab samples and one saliva sample will be collected from each subject. The saliva sample will be tested with the COVIDSeq Test and one nasal swab will be tested with an EUA approved COVID test. The other nasal swab sample will be stored and a subset (approximately 250 specimens) will be tested with the COVIDSeq Test. Results of all testing will be provided to the sponsor for statistical analysis.

Positive results from COVIDSeq Test using saliva and/or the comparator EUA test will be provided to subjects so participants can be referred for further evaluation (outside the study). No medical treatment, guidance on treatment decisions, nor medical care will be provided. "

Detailed Description

Not available

Study Timeline

• Study Start: 2020-02-13
• Study First Submitted: 2020-09-21
• Study First Submitted QC: 2020-09-22
• Study First Posted: 2020-09-23
• Primary Completion: 2021-02-28
• Study Completion: 2021-02-28
• Status Verified: 2022-01
• Last Update Submitted: 2022-01-20
• Last Update Posted: 2022-01-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 763

Inclusion Criteria

An individual must meet the criteria below to be eligible.

• Individual is Illumina US personnel (eg, employee, contractor, consultant) and was invited to participate in the study.
• Individual is 18 years or older at the time of consent.
• Individual is feeling well and, at the time of consent or specimen collection, does not have any of the following symptoms of COVID-19: cough, shortness of breath or difficulty breathing, fatigue, fever or chills, muscle or body aches, headache, sore throat, new loss of taste or smell, congestion or runny nose, nausea or vomiting, or diarrhea. [1]
• Individual is willing to participate in study procedures and able to provide written informed consent in the English language.

Subject

Exclusion Criteria

An individual cannot meet the below criteria.

• Individual is confirmed to have COVID-19 and continues to require home isolation in accordance with current CDC guidelines at the time of consent or specimen collection.
• Individual is asymptomatic but suspected to have COVID-19 due to recent close contact (as currently defined by the CDC) with a person with COVID-19 and continues to require quarantine in accordance with current CDC guidelines at the time of consent or specimen collection. [4]
• Individual had symptoms of COVID-19 less than 10 days before time of consent or less than 10 days before time of any subsequent specimen collection visit."

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
COVID-19 asymptomatic population	COVIDSeq Test	COVID-19 asymptomatic Illumina personnel

Primary Outcome Measures

Name	Time	Method
Positive percent agreement (PPA) and negative percent agreement (NPA) between the COVIDSeq Test and a comparator EUA test for the detection of SARS-CoV-2 RNA	1 month

Trial Locations

Locations (2)

Illumina Hayward; 🇺🇸 Hayward, California, United States

Illumina Laboratory Services; 🇺🇸 San Diego, California, United States